Smokers Who Quit Before Age 45 Significantly Reduce Risk of Lung Cancer

Industry Insight
Jun.09.2022
Smokers Who Quit Before Age 45 Significantly Reduce Risk of Lung Cancer
A new study conducted by the American Cancer Society highlighted that while quitting smoking reduces cancer risks at any age, doing so before the age of 45 nearly eliminates all risk.

Titled, “Association of Smoking Initiation and Cessation Across the Life Course and Cancer Mortality Prospective Study of 410 000 US Adults,” the study of over 400,000 Americans, found that smokers are three times more likely to die of a tobacco-related cancer than nonsmokers.

 

However, reported the researchers, quitting by age 45 reduces this risk by 89%, while for those who quit before they are 35, the risk is completely eliminated. On the other hand, quitting between ages 45-54 still reduces the risk by a significant 78%, while doing so between ages 55-64 cuts it by 56%.

 

The research team found that similarly, the age of smoking initiation also has an impact on cancer risk. People who started smoking before age 18 had at least three times the risk of dying from cancer, while those who started before age 10 had four times the risk.

 

Tobacco use behavior following a cancer diagnosis

 

Another recent study published in Annals of Internal Medicine, found that quitting smoking following a lung cancer diagnosis may prevent cancer recurrence and extend life. Titled, “Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality,” the study was conducted by researchers from the International Agency for Research on Cancer, the specialized cancer agency of the World Health Organization, in collaboration with the N.N. Blokhin National Medical Research Centre of Oncology in Russia. The research team recruited 517 current adults who were current smokers when they were diagnosed with early-stage non-small cell lung cancer from 2 sites in Moscow, Russia.

 

At the start of the study the participants were interviewed to determine medical and lifestyle history, including tumor characteristics, and their tobacco use patterns. Each participant was followed each year for an average of 7 years in a bid to record any changes in their smoking behavior.

 

Of 517 lung cancer patients who were smokers when diagnosed, less than half quit (44.5%), and very few relapsed. The patients who quit smoking were more likely to live longer overall (6.6 years vs. 4.8. years), live longer without lung cancer (5.7 vs. 3.9 years) and have their disease progress at a slower rate (7.9 vs. 6 years).

 

In light of these findings, the research team concluded that quitting smoking after being diagnosed with early-stage non-small cell lung cancer may slow disease progression and decrease mortality.

 

Source:VapingPost

French Anti-Tobacco Group Questions PMI’s IQOS “Curiosity” Campaign Over Potential Youth Appeal
French Anti-Tobacco Group Questions PMI’s IQOS “Curiosity” Campaign Over Potential Youth Appeal
According to French anti-tobacco group Générations Sans Tabac, Philip Morris International’s (PMI) IQOS “Curiosity” campaign has drawn attention from public health advocates. The group argues that the campaign uses themes including curiosity, exploration and lifestyle branding that could increase interest among younger audiences. PMI has positioned IQOS as a key part of its smoke-free product strategy, while France maintains strict restrictions on tobacco and nicotine product marketing. The debate highlights ongoing tensions between heated tobacco branding strategies and public health concerns in Europe.
Jul.24
WIRED Investigation: Chinese-Made Vapes Turn to 6-Methyl-Nicotine and Other Analogs, Challenging U.S. Regulation
WIRED Investigation: Chinese-Made Vapes Turn to 6-Methyl-Nicotine and Other Analogs, Challenging U.S. Regulation
U.S. technology and investigative publication WIRED has examined how nicotine analogs are emerging as a new challenge for the country’s vape regulatory framework. The article argues that after the U.S. expanded federal oversight of nicotine products in 2022, some manufacturers began using nicotine-like compounds such as 6-methyl-nicotine that may fall outside existing definitions. Researchers cited by WIRED said some nicotine analogs could be more potent than traditional nicotine, although human health impacts remain unclear. U.S. policymakers are considering broader definitions of nicotine to bring these compounds under federal oversight.
Jul.27
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
Altria’s USSTC Starts $250 Million Kentucky Expansion, Adding More Than 200 Jobs
U.S. Smokeless Tobacco Company, an Altria Group company, has broken ground on an approximately $250 million manufacturing expansion in Hopkinsville, Kentucky. The roughly 270,000-square-foot facility is expected to create more than 200 jobs and absorb processing, manufacturing and packaging operations currently split between Hopkinsville and Nashville, Tennessee. USSTC previously said production at its Nashville facility is expected to wind down by early 2028. The project forms part of Altria’s broader effort to modernize and consolidate its U.S. smokeless tobacco manufacturing network.
Sep.10
UK Reform Party Proposes Cap of 1,000 Vape Shops Under Plan to Tighten Retail Controls
UK Reform Party Proposes Cap of 1,000 Vape Shops Under Plan to Tighten Retail Controls
The UK Reform Party has proposed limiting the number of dedicated vape shops in the country to around 1,000 as part of a plan to tighten oversight of vape retail channels. The proposal was put forward by Reform UK deputy leader and MP Lee Anderson. The plan remains a political proposal and has not become UK government policy, with no detailed legislation, implementation timeline or allocation rules announced.
Aug.10
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26
BREAKING | China’s Tobacco Regulator Summons iMiracle Over Suspected Compliance Breaches
BREAKING | China’s Tobacco Regulator Summons iMiracle Over Suspected Compliance Breaches
Based on public records reviewed by 2Firsts, this is the first time China’s State Tobacco Monopoly Administration has publicly announced regulatory talks with an e-cigarette company.
Jul.29